MARKET

XBIT

XBIT

XBiotech
NASDAQ

Real-time Quotes | Nasdaq Last Sale

19.15
+0.21
+1.11%
Opening 13:10 02/24 EST
OPEN
18.90
PREV CLOSE
18.94
HIGH
19.43
LOW
18.61
VOLUME
39.25K
TURNOVER
--
52 WEEK HIGH
21.48
52 WEEK LOW
8.72
MARKET CAP
560.34M
P/E (TTM)
2.041
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Interleukin 1 (IL1) Market Size Research Report 2021 by Growth Drivers, Market Challenges, Restraints, Price and Forecast to 2027 Says Absolute Reports
The Express Wire · 2d ago
Interleukin 1 (IL1) Market By Manufacturers, Types, Regions and Application and Forecast 2020 to 2027 By Ameco Research
pune, India, Mon, 22 Feb 2021 00:30:48 / Comserve Inc. / -- Interleukin 1 (IL1) market is segmented by Type, and by Application. Players, stakeholders, and...
Comserve · 2d ago
Global Antibiotics Market By Action Mechanism, By Drug Class, By Region, Industry Analysis and Forecast, 2020 - 2026
New York, Feb 10, 2021 (GLOBE NEWSWIRE via COMTEX) -- New York, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report...
GlobeNewswire · 02/10 12:45
Cancer Cachexia Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast 2020 to 2027
Market Insight Reports · 02/04 05:46
True Human(TM) COVID-19-Therapiekandidat von XBiotech zielt auch auf neuen hochinfektiosen Stamm ab
Vor dem Hintergrund der rasanten Ausbreitung des neuen hochinfektiosen Stamms liefert XBiotech Daten, die darauf hinweisen, dass sein True Human(TM) COVID-19-Therapiekandidat auch bei der Behandlung der Virusmutation wirksam sein konnte
Globe Newswire · 01/22 08:03
DJ XBiotech Vaccine Candidate Can Be Used in New Covid-19 Strain
Dow Jones · 01/21 13:34
XBiotech Candidate True Human(TM) COVID-19 Therapy Found to Target Highly Infectious Emerging Strain
AUSTIN, Texas, Jan 21, 2021 (GLOBE NEWSWIRE via COMTEX) -- AUSTIN, Texas, Jan. 21, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announces that its...
GlobeNewswire · 01/21 13:15
XBiotech Candidate True Human(TM) COVID-19 Therapy Found to Target Highly Infectious Emerging Strain
With New Infectious Strain Rapidly Spreading, XBiotech Establishes Data Indicating its Candidate True Human(TM) COVID-19 Therapy may be Effective for Treating New Mutant Strain
Globe Newswire · 01/21 13:15
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of XBIT. Analyze the recent business situations of XBiotech through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average XBIT stock price target is 18.00 with a high estimate of 18.00 and a low estimate of 18.00.
EPS
Institutional Holdings
Institutions: 98
Institutional Holdings: 4.02M
% Owned: 13.72%
Shares Outstanding: 29.26M
TypeInstitutionsShares
Increased
18
115.62K
New
15
108.98K
Decreased
22
173.19K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.99%
Pharmaceuticals & Medical Research
+1.32%
Key Executives
Chairman/President/Chief Executive Officer/Founder/Director
John Simard
Chief Financial Officer
Scott Whitehurst
Chief Scientific Officer
Sushma Shivaswamy
Vice President - Finance/Director of Human Resources/Secretary
Queena Han
Lead Director/Independent Director
Jan-Paul Waldin
Independent Director
Peter Libby
Independent Director
Donald MacAdam
Independent Director
W. Thorpe McKenzie
  • Dividends
  • Splits
  • Insider Activity
No Data
About XBIT
XBiotech Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Human monoclonal antibodies for treating a range of different diseases. It focuses on its lead product candidate, Xilonix (MABp1), which is derived from a natural human immune response. The Company has also developed a True Human monoclonal antibody discovery platform and manufacturing system. Xilonix is a therapeutic antibody, which specifically neutralizes interleukin-1 alpha (IL-1a). Its pipeline includes various human antibodies for treating diseases, such as cancer, vascular disease, inflammatory skin disease and diabetes. The Company has completed a Phase III study in Europe for the treatment of symptomatic colorectal cancer. It also investigated its lead product candidate in clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS).

Webull offers kinds of XBiotech Inc stock information, including NASDAQ:XBIT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XBIT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading XBIT stock methods without spending real money on the virtual paper trading platform.